US Bancorp vs Zoetis Inc — how do they compare? US Bancorp trades at $64.47 (market cap $100.17B), while Zoetis Inc trades at $73.51 (market cap $31.14B). The key difference: US Bancorp is far larger — about 3.2× Zoetis Inc's market cap, and US Bancorp pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| USB | ZTS | |
|---|---|---|
Market Cap | $100.17B | $31.14B |
Sector | Financials | Health |
52-Week High | $64.47 | $156.76 |
52-Week Low | $45.28 | $71.91 |
Dividend Yield | 3.24% | 2.81% |
Enterprise Value | — | $38.70B |
Signals from Pluang's Aura AI — not financial advice
U.S. Bancorp (USB) trades at $64.19, up 0.39% today, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.35 surpassing the $1.28 expectation. Revenue and net income have shown steady growth, with 2025 revenue at $28.54 billion and net income at $7.57 billion. Analyst sentiment is positive, with a consensus price target of $70.27, indicating potential upside.
The outlook for USB is favorable, supported by robust earnings growth, a solid dividend, and positive analyst ratings. Key risks include exposure to interest rate fluctuations and macroeconomic volatility, as highlighted by recent news on potential Fed rate hikes. Institutional investors have been increasing stakes, reinforcing confidence. The stock presents a compelling opportunity for value-oriented investors seeking steady returns amid a stable banking sector.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Trailing returns across standard periods
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →